论文部分内容阅读
目的： 研究ｐ１６ 与增殖性细胞核抗原（ Ｐ Ｃ Ｎ Ａ）蛋白在各级人脑胶质瘤中的表达率及与胶质瘤病理分级的关系．方法： 利用免疫组化方法检测５２ 例胶质瘤手术标本中ｐ１６ 与 Ｐ Ｃ Ｎ Ａ 蛋白的表达水平，并比较二者的相关性，及其与胶质瘤病理分级的关系． 结果： 随着胶质瘤病理级别的升高ｐ１６ 蛋白的表达率逐渐降低， Ⅰ～Ⅳ级阳性率分别为 ７５． ０％ ，６４７％ ，４２．８％ 和３３．３％ ，低度恶性组（Ⅰ～Ⅱ级）与高度恶性组（Ⅲ～Ⅳ级）有显著差异（ Ｐ＜ ０．０５）． Ｐ Ｃ Ｎ Ａ 表达强度随胶质瘤病理级别的升高而增加（ Ｐ＜ ０．０５）． 所选病例的平均 Ｐ Ｃ Ｎ Ａ 指数（ Ｐ Ｃ Ｎ Ａ Ｌ Ｉ）为 ２７．１， ｐ１６ 与 Ｐ Ｃ Ｎ Ａ 表达存在负相关（ｒ＝ ０．４８５， Ｐ＜ ０．０５）． 结论： ｐ１６ 及 Ｐ Ｃ Ｎ Ａ 蛋白的表达对分析判断胶质瘤病理分级的适用性及恶性转化具有一定意义．
Objective: To investigate the expression of p16 and proliferating cell nuclear antigen (P C N A) in human glioma at various stages and its relationship with the pathological grade of glioma. Methods: Immunohistochemistry was used to detect the expression of p16 and P C N A protein in 52 glioma specimens. The correlation between them and their correlation with glioma pathological grade were also analyzed. Results: With the pathological grade of glioma, the expression of p16 protein gradually decreased. The positive rates of grade Ⅰ ~ Ⅳ were 75%. 0%, 647%, 42.8% and 33.3% respectively. There was a significant difference (P <0.05) between low grade malignant group (grade Ⅰ ~ Ⅱ) and high grade group (grade Ⅲ ~ Ⅳ). The expression of P C N A increased with the pathological grade of glioma (P <0.05). The mean P C N A L I of the selected cases was 27.1. There was a negative correlation between p16 and P C N A (r = 0.485, P <0.05). Conclusion: The expressions of p16 and P C N A have some significance for the analysis of the applicability and malignant transformation of glioma pathological grading.